PURPOSE The primary objective of the Children's Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology-and response-based algorithm to assign treatment duration while maintaining a 3-year overall survival (OS) of 95% or more for the entire cohort.
INTRODUCTION
Neuroblastoma is characterized by a broad array of clinical behavior, 1, 2 and biomarkers are used to classify risk and stratify treatment. 3 Previous multiinstitutional and cooperative group risk-based clinical trials have led to substantial improvement in outcomes for children with neuroblastoma, 4 with increasingly intensive multimodality approaches for high-risk patients [5] [6] [7] [8] and successive reductions in therapy for patients with low-and intermediate-risk disease. [9] [10] [11] The overall objective of Children's Oncology Group (COG) ANBL0531 (ClinicalTrials.gov identifier: NCT00499616) was to further reduce chemotherapy exposure and surgical morbidity for subsets of intermediate-risk patients while maintaining 90% or greater 3-year overall survival (OS) within each clinical and biologic biomarker-defined treatment stratum (group) and 95% or greater 3-year OS for the entire cohort. The study also tested the efficacy of a standard retrieval approach for patients who developed progressive, nonmetastatic disease. on the basis of a historical cohort. Chemotherapy treatment assignment was stratified by the degree of surgical resection for patients with stage 2A/2B tumors, the presence of symptoms for patients with stage 4S disease, the allelic status of chromosomes 1p36 and 11q23, 12 age at diagnosis, International Neuroblastoma Staging System (INSS) stage, histology, MYCN status, and ploidy.
Patients and Tumor Assessments
Patients were staged according to the INSS, 13 and response was assessed using a protocol-specific modification of the International Neuroblastoma Response Criteria. 13 Primary tumor response was defined by tumor volume as follows: partial response (PR; 50% to 90% reduction), very good PR (VGPR; greater than 90% reduction), or complete response. Tumors were classified as favorable or unfavorable biology on the basis of ploidy for infants younger than 365 days and toddlers age 365 to younger than 547 days with stage 4 disease, histology (favorable histology [FH], unfavorable histology [UH]) according to the International Neuroblastoma Pathology Classification system, 14 and the allelic status of chromosome 1p36 and 11q23. Patients with MYCN-amplified tumors were excluded. The study cohort included patients 12 years of age or younger with stage 2A/2B tumors with less than 50% resection or biopsy only, infants younger than 365 days with stage 3 or 4 neuroblastoma, patients 365 days to 12 years of age with FH stage 3 tumors, toddlers age 365 days to younger than 547 days with UH stage 3 disease, toddlers age 365 to younger than 547 days with stage 4 biologically favorable tumors (FH, hyperdiploid, any 1p/11q status), and infants younger than 365 days with stage 4S neuroblastoma who were either symptomatic or had biologically unfavorable (UH, diploid) tumors. The cohort of patients with stage 4S disease was reported separately. 15 Written informed consent was obtained from parents or guardians after the study was approved by the National Cancer Institute Pediatric Central institutional review board and the local institutional review board.
MYCN copy number was determined by fluorescence in situ hybridization, 16 DNA index by flow cytometry, 17 and allelic status of 1p36 and 11q23 by polymerase chain reaction-based analysis of microsatellite repeat loci, all at the COG reference laboratory. Histology was centrally reviewed and classified according to the International Neuroblastoma Pathology Classification system. 14 
Initial Treatment Assignment
Eligible patients were assigned to initially receive two (group 2), four (group 3), or eight (group 4) cycles of chemotherapy on the basis of age at diagnosis, INSS stage, histology, and genetic features of the tumor. If data were missing for any tumor biomarker, the result was classified as unfavorable. Table 1 lists the clinical and biologic characteristics of the patients initially assigned to groups 2, 3, and 4 and shows the comparison of treatment assignments in ANBL0531 versus the legacy COG clinical trials. Group 1 patients were not eligible for this trial.
The chemotherapy regimens in ANBL0531 and A3961 (ClinicalTrials.gov identifier: NCT00003093) were the same 10 (Appendix Table A1 , online only). Second-look surgery of the primary tumor was scheduled after the assigned number of chemotherapy cycles, although not required for group 2 and 3 patients who achieved PR or better of the primary tumor with chemotherapy alone. The treatment end point for group 3 patients with stage 4 or 4S disease was resolution of nonliver/nonskin metastases and PR or better of the primary tumor. Group 2 and 3 patients who did not achieve the treatment end point with the assigned regimen received up to eight cycles of front-line chemotherapy, and up to six additional cycles of cyclophosphamide and topotecan (CPM + TOPO; Appendix Table A1 ). The treatment end point for all group 4 patients was VGPR or better of the primary tumor and resolution of nonliver/nonskin sites for patients with metastatic disease. Six cycles of isotretinoin were administered to group 4 toddlers who achieved a VGPR or better after eight cycles of chemotherapy with or without surgery (Appendix Table A1 ). Group 4 patients who did not achieve VGPR were treated with CPM plus TOPO.
For tumors with intraspinal extension and cord compression, the criteria to stop therapy included the achievement of both the group-defined treatment end point and sufficient shrinkage of the intraspinal tumor to minimize the risk of ongoing or impending neurologic impairment. Laminectomy for surgical debulking was not recommended as primary therapy.
Retrieval Therapy for Progressive, Nonmetastatic Disease
Up to six cycles of CPM plus TOPO (Appendix Table A1 ) were used as salvage therapy for progressive, nonmetastatic disease within 3 years of study enrollment. The treatment end point was VGPR. Patients with recurrent or progressive metastatic disease at any time were removed from protocol therapy.
Toxicity Monitoring
All patients underwent evaluations of hematologic, hepatic, and renal function every 3 weeks. Cardiac function was evaluated at diagnosis, after cycle 4, and at end of therapy. Auditory function was assessed at diagnosis and end of therapy. Toxic effects were defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0), and all grade 3 or greater toxicities were documented. from the date of diagnosis to the first occurrence of an event (relapse, progression, death as a result of any cause, or secondary cancer). Patients who did not die (OS) or experience an event (EFS) were censored on the date of last contact. The analyses of EFS and OS were performed as intention to treat. Survival estimates on the basis of the Kaplan-Meier method 18 were reported at 3 years, with SEs per Peto et al. 19 Interim monitoring for sufficiently high 3-year EFS was conducted within each group as an early surrogate for OS. In addition, patients age 365 days to younger than 547 days were monitored for early relapse/ progression as an indication that reduction in therapy was unsuccessful. Complete statistical considerations are found in the study protocol (Data Supplement).
The primary analysis applied herein differs from the original protocol plan; it was not possible to implement the planned analysis of a comparison of ANBL0531 with an analogous historical cohort because of missing risk factor data, including 1p and 11q status. For the primary objective, the sample size provides sufficient precision for placement of a 95% CI (n = 404; SE, 1.13%; interval width, 4.43%) on the 3-year OS. 20 If the upper limit of the 95% CI was above the benchmark (95% overall, 90% within each group), we would conclude that the observed 3-year OS was not statistically significantly lower than the benchmark. Two-sided log-rank tests were used to compare survival curves by subgroups.
RESULTS

Patient Characteristics, Group Assignment, and Treatment
Patients (N = 464) were enrolled between October 8, 2007, and June 30, 2011. Eighteen were deemed ineligible, and 42 were excluded because they were subsequently classified as high risk (Fig 1) . The study cohort comprised the remaining 404 evaluable patients. Initial treatment assignments and patient characteristics are listed in Tables 1  and 2 . Compared with the legacy COG trials, 9,10 therapy reduction for group 2 and 3 patients was prescribed by assignment to fewer chemotherapy cycles and/or by the targeted PR treatment end point for the primary site rather than VGPR. Initial treatment assignment also was reduced significantly for group 4 toddlers with stage 3 or 4 disease (n = 10) previously treated with high-risk regimens. 5 Treatment assignment for infants with stage 3 or 4 disease with either diploid or UH tumors was unchanged from A3961. However, for group 4 infants with hyperdiploid, FH stage 4 disease with loss of heterozygosity (LOH) at 1p36/ 11q23 or missing allelic status data (n = 32), initial treatment assignment was increased.
Treatment received according to initial group assignment is listed in 
Surgery and Radiotherapy
Surgical data were available for 391 patients (96.8%). At diagnosis, 33 patients underwent more than 90% tumor resection, 21 underwent between 50% and 90% resection, and 337 had a biopsy only or less than 50% resection. The degree of resection at diagnosis was unknown in eight patients, and five infants with stage 4S disease did not undergo a diagnostic procedure. Secondlook surgery was performed after chemotherapy in 38 patients; 28 had more than 90% resection, eight had between 50% and 90% resection, and two underwent a less than 50% resection. (n = 1) (n = 2) (n = 3) (n = 1) (n = 1) No significant difference in OS was observed according to the degree of resection at diagnosis (more than 90% resection v between 50% and 90% resection, biopsy only, or less than 50% resection; P = .74). Surgery-related complications were reported in 38 patients (9.7%), including pulmonary complications (2.0%), intestine or liver resection (0.8%), and/or wound infection (0.5%). No vascular or nerve injuries were reported, and no patient underwent nephrectomy. Eight patients received radiotherapy, including five for progressive hepatomegaly 15 and three with spinal cord compression. 
Chemotherapy-Related Toxicity
Reversible myelosuppression was the most commonly observed grade 3 or greater toxicity (Appendix Table A2 , online only). Nonhematologic organ toxicity was rare, and no patient reported hearing loss.
Up to six additional chemotherapy cycles of CPM plus TOPO were administered to 27 patients (Table 3 ; Appendix Table  A3 , online only): 20 because of inadequate response to initial therapy (Appendix Table A4 , online only), and seven because of development of progressive, nonmetastatic disease.
Toxicities associated with cycles 9 to 14 included neutropenia in 44.4% of patients and infections in 22.2%. Similar toxicities were observed in the seven patients who received up to six cycles of salvage therapy after developing progressive, nonmetastatic disease (Appendix Table A3 ).
Survival According to Initial Group Assignment and 1p36/ 11q23 Allelic Status
Three-year EFS and OS rates for the entire study cohort were 83.2% (95% CI, 79.4% to 87.0%) and 94.9% (95% CI, 92.7% to 97.2%), respectively (Fig 2A) . The respective 3-year EFS rates for group 2 (n = 175), group 3 (n = 141), and group 4 (n = 88) patients were 87.2% (95% CI, 82.0% to 92.4%), 86.5% (95% CI, 80.8% to 92.2%), respectively, and 69.5% (95% CI, 59.6% to 79.5%; Fig 2B) 
Disease Progression and Death
Seven patients with progressive, nonmetastatic disease were treated with the prescribed salvage regimen; six remain alive, three experienced relapse (two metastatic), and one died. With the exclusion of these seven patients, events occurred in 63 patients, including disease progression (n = 53 [24 metastatic, 28 locoregional progression, one unknown]), death as first event (n = 9), and secondary malignancy (one acute myeloid leukemia). Twenty-one patients died. Causes of death were complications of hepatomegaly in infants younger than 90 days of age (n = 5); relapsed metastatic disease (n = 7); and death as a result of other causes, including infection (n = 3), liver transplantation (n = 1), second malignancy (n = 1), and drowning (n = 1). The cause of death for three patients is unknown.
DISCUSSION
Treatment duration in ANBL0531 was assigned according to clinical features and a tumor biology-and responsebased algorithm. In addition to established COG risk group criteria, treatment was stratified by allelic status of 1p36 and 11q23. 12 Compared with the legacy study, 10 an increase in treatment duration was prescribed for a subset of infants with stage 4 FH, hyperdiploid tumors with 1p36 and/or 11q23 LOH (or unknown allelic status), whereas treatment was reduced for specific subsets of patients with favorable biology tumors, including normal 1p36 and 11q23. Additional therapy reduction was achieved by using PR of the primary tumor as the end point of therapy for group 2 and 3 patients in lieu of VGPR. 10 Only 90 patients (23%) required surgery to achieve PR or better of the primary site, which reflects the efficacy of the chemotherapy regimen. Subgroups of toddlers ages 365 to younger than 547 days with stage 3 and 4 disease, [21] [22] [23] previously classified as high risk, received significantly reduced therapy on the basis of the favorable outcome observed in previous studies. 21, 22 Three-year EFS and OS rates of 88% (95% CI, 84% to 90%) and 96% (95% CI, 94% to 97%), respectively, were achieved in the A3961 study 10 demonstrated excellent survival with reductions in treatment of infants with unresectable locoregional tumors or with disseminated disease that lacked MYCN amplification. 24, 25 Excellent outcome also was achieved in ANBL0531, with 3-year EFS and OS rates of 83.2% (95% CI, 79.4% to 87.0%) and 94.9% (95% CI, 92.7% to 97.2%), respectively. An analogous comparison with a historical cohort (primarily A3961 10 ), as originally planned, was not possible because the criteria used to classify patients as intermediate risk were modified in 2007 26 unknown in the historical data. In addition, the revised eligibility criteria for ANBL0531 did not align with A3961. Specifically, patients with stage 2A/2B disease with less than 50% resection were eligible for ANBL0531, whereas these patients were previously classified as low risk. 9 In addition, infants with stage 4S disease with unknown biology were eligible for this study. Furthermore, two toddler cohorts (ages 365 to younger than 547 days) previously classified as high risk 5 were eligible for ANBL0531. Although none of the 10 toddlers have died, additional studies with larger numbers of patients will be needed to assess further the efficacy of intermediate-risk therapy in this cohort.
Numerous studies have demonstrated an association between 1p36 or 11q23 LOH and inferior survival of children with neuroblastoma. 27, 28 More-recent studies that analyzed the whole genome have demonstrated that other segmental chromosomal abnormalities (SCAs) also are associated with poorer outcome. 29, 30 Previously, the presence of 1p36 or 11q23 LOH was shown to be independently associated with decreased progression-free survival in a multivariable model among low-and high-risk patients, 12 and a significantly inferior EFS also was seen for patients enrolled in ANBL0531 whose tumors harbored 11q23 LOH. However, EFS was not significantly different for patients with tumors with versus without 1p36 LOH, which indicates that the prognostic value of specific SCAs differs in this cohort.
Using primary tumor PR as a treatment end point for favorable biology tumors was a successful strategy, with 100% survival observed in patients with localized disease. Treatment was not reduced for infants with hyperdiploid, FH, stage 4 disease with normal 1p36/11q23 compared with that in A3961, 10 and excellent EFS and OS were observed. Future prospective studies will be needed to determine whether it is possible to achieve excellent outcome with reduced therapy for this cohort. For the 32 infants with hyperdiploid, FH, stage 4 tumors with LOH at 1p36 or 11q23 or missing LOH data, intensification of treatment in ANBL0531 compared with A3961 10 did not reduce the risk of relapse previously reported for infants with tumors that harbor an SCA genomic profile. 31 The 3-year EFS rate for this cohort was 68.6% (95% CI, 52.2% to 85.1%) v 86.9% (95% CI, 78.3% to 95.4%) for infants with stage 4 disease with favorable biology (P = .04). OS was not significantly different, which indicates that many of the infants with 1p36/11q23 aberrations underwent successful salvage therapy. Of the 20 patients who received CPM plus TOPO because of an inadequate response to initial therapy, nine achieved VGPR or better. However, six of the 20 patients developed progressive disease or experienced relapse, and one died, which indicates that more-effective treatment is needed for patients who do not meet the defined treatment end point after eight cycles of chemotherapy (Appendix Table A4 ).
It is important to emphasize that intermediate-risk neuroblastoma is a heterogeneous collection of neuroblastoma phenotypes. Using this response-and biology-based algorithm that includes the allelic status of 1p36 and 11q23, excellent survival was achieved with refined treatment strategies for specific subsets of intermediate-risk patients.
In extension of these results, the observation of favorable biology L2 tumors that lack SCAs in patients younger than 18 months of age is being evaluated in COG ANBL1232 (ClinicalTrials.gov identifier: NCT02176967). Additional genomic biomarkers also are being investigated in ANBL1232, in European clinical trials, 32 and through the ongoing Therapeutically Applicable Research to Generate Effective Treatments genomic sequencing initiative. 33 The incorporation of these biomarkers may enable more precise prognostication and treatment stratification, which will improve further the outcome for children with intermediaterisk neuroblastoma. 
APPENDIX
